Get started
Author

Saman Maleki Vareki

Observed names: Maleki Vareki, Saman, S Maleki Vareki, S. Maleki Vareki, S. Maleki-Vareki, Saman MalekiVareki, Samen Maleki Vareki, Vareki, Saman Maleki
Observed institutions: Ontario Institute for Cancer Research, Isfahan University of Medical Sciences, Western University, Lawson Health Research Institute, University of Ottawa, London Health Sciences Centre, University of Isfahan, Lawson Research Institute, London Health Sciences Centre Research Institute
ORCID: 0000-0002-9615-7779
Observed ORCID: 0000-0002-9615-7779
OpenAlex ID: A5084060241
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
2018 · Saman Maleki Vareki · Journal for ImmunoTherapy of Cancer · 568
PDF
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
2023 · Bertrand Routy, John G. Lenehan, et al. · Nature Medicine · 516
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis
2020 · Syed Hussaini, Rania Chehade, et al. · Cancer Treatment Reviews · 397
Biomarkers of response to PD-1/PD-L1 inhibition
2017 · Saman Maleki Vareki, Carmen Garrigós, et al. · Critical Reviews in Oncology/Hematology · 318
PDF
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
2016 · Penka S. Petrova, Natasja Nielsen Viller, et al. · Clinical Cancer Research · 278
The Microbiome and Genitourinary Cancer: A Collaborative Review
2019 · Mark C. Markowski, Stephen A. Boorjian, et al. · European Urology · 183
COTI-2, a novel small molecule that is active against multiple human cancer cell linesin vitroandin vivo
2016 · Kowthar Y. Salim, Saman Maleki Vareki, et al. · Oncotarget · 152
PDF
Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy
2018 · Steven F. Gameiro, Farhad Ghasemi, et al. · OncoImmunology · 139
The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer
2022 · Azin Aghamajidi, Saman Maleki Vareki · Cancers · 99
PDF
Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
2021 · Mithunah Krishnamoorthy, Lara Gerhardt, et al. · Cells · 92
PDF
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial
2026 · Sreya Duttagupta, Meriem Messaoudene, et al. · Nature Medicine · 85
PDF
The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development
2025 · Arielle Elkrief, Reilly Pidgeon, et al. · Nature Reviews Drug Discovery · 85
Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges
2020 · Mithunah Krishnamoorthy, John G Lenehan, et al. · JNCI Journal of the National Cancer Institute · 76
PDF
Microbiome bacterial influencers of host immunity and response to immunotherapy
2024 · Yeganeh Yousefi, Kelly J. Baines, et al. · Cell Reports Medicine · 55
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
2025 · Tricia R Cottrell, Michael T Lotze, et al. · Journal for ImmunoTherapy of Cancer · 53
CD1d‐independent activation of mouse and human iNKT cells by bacterial superantigens
2011 · Jacqueline L Hayworth, Delfina M Mazzuca, et al. · Immunology and Cell Biology · 51
Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin
2014 · Saman Maleki Vareki, Mateusz Rytelewski, et al. · Oncotarget · 50
PDF
Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy
2022 · Megan M Y Hong, Saman Maleki Vareki · Cancers · 48
PDF
The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
2021 · Abdul Rafeh Naqash, Alba J. Kihn-Alarcón, et al. · Annals of Translational Medicine · 47
PDF
Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines
2018 · Saman Maleki Vareki, Kowthar Y. Salim, et al. · PLoS ONE · 46
PDF
Microbiota activation and regulation of adaptive immunity
2024 · Mozhdeh Heidari, Saman Maleki Vareki, et al. · Frontiers in Immunology · 43
PDF
BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma
2019 · Brian W. Labadie, Ping Liu, et al. · Journal of Translational Medicine · 43
PDF
Dissecting mechanisms of fecal microbiota transplantation efficacy in disease
2024 · Catherine M. Andary, Kait F. Al, et al. · Trends in Molecular Medicine · 41
Emerging Biomarker-Guided Therapies in Prostate Cancer
2022 · Jasna E. Deluce, Luisa Cardenas, et al. · Current Oncology · 41
PDF
CD5 blockade enhances ex vivo CD8 + T cell activation and tumour cell cytotoxicity
2020 · Faizah Alotaibi, Mateusz Rytelewski, et al. · European Journal of Immunology · 41
PDF
Works count: 102
Citation count: 4,176
H-index: 32
I10-index: 48
Year
Topic
Type